David Wallace

In this exclusive two-part interview, @Amgen's Chad Pettit, @AmgenBiosim commercial lead, talks to @Genericbulletin about the firm’s “unique perspective” on biosimilars, including how competition to Humira is expected to signal a major shift in the US biosimilars landscape.

Generics bulletin @Genericbulletin

Amgen Calls For Balance To Support Biosimilars https://t.co/VkOeMIqePI

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, says AmerisourceBergen’s (@Healthcare_ABC’s) senior vice president for global emerging therapies and channel strategy, Beth McMahon.

Generics bulletin @Genericbulletin

Competition Intensifies As Access Increases For US Biosimilars https://t.co/ZOC6Kaqi40

In an exclusive two-part interview, @SamsungBioepis development division leader Kyung-ah Kim and @biogen global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

Generics bulletin @Genericbulletin

Supply Security And Competitive Pricing Will Support Byooviz Launch In US https://t.co/o0E9MTV0CI

In this two-part interview, I talk to @hikmapharma CEO Siggi Olafsson about how Hikma expects to maintain its deal-making momentum, future plans for US biosimilars, and how it is positioned to deal with pricing pressures and increased competition on some of its key generics.

Generics bulletin @Genericbulletin

Hikma Has An Appetite For More Deals As It Builds On Acquisitions https://t.co/nzih7xAS6u

Sonia Oskouei, @cardinalhealth VP of biosimilars, talks about how real-world evidence and education can build confidence in biosimilars, as well as the ongoing struggle against misinformation and need for clarity over concepts such as interchangeability and unbranded biologics.

Generics bulletin @Genericbulletin

Evidence And Education Must Support US Biosimilars https://t.co/zAgxA8bVcm

RT @AccessibleMeds: In this @Pharma_Intell interview, #AAMBoard Vice Chair Christine Baeder (Senior Vice President, Chief Operating Officer…

A major biosimilars deal between @Bioconlimited and @ViatrisInc to kick off this week:

Generics bulletin @Genericbulletin

Biocon Pays $3.3bn For Viatris Biosimilars Business https://t.co/cgs8rl0cFd

With key milestones on the horizon for US biosimilars in 2022 and 2023, @cardinalhealth VP of biosimilars Sonia Oskouei explains how the industry can best position itself to take advantage of upcoming opportunities, including potentially a global leadership role in ophthalmology.

Generics bulletin @Genericbulletin

US Has Opportunity To Lead On Ophthalmic Biosimilars https://t.co/w3Ec0Va8P6

RT @USBiosimilars: Biosimilars Forum executive director Juliana Reed discusses the Forum's priorities and leadership in the #biosimilars in…

In an exclusive interview with Generics Bulletin, the @USBiosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.

Generics bulletin @Genericbulletin

Reed Sets Out Priorities For US Biosimilars Forum https://t.co/iUFN4aCg3e

RT @RobertWessman: This is the first part of an exclusive two-part interview with David Wallace at @Genericbulletin, where I talk about Alv…

In the second part of an exclusive two-part interview with Generics Bulletin, @alvotechpr founder and chairman @RobertWessman sets out the firm’s expectations for its rival to Humira as it continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

Generics bulletin @Genericbulletin

Alvotech Could Upend Expectations For US Humira Biosimilars https://t.co/EuEgLj4QYD

Alvotech founder and chairman @RobertWessman tells Generics Bulletin how the firm plans to move forward following recently-revealed plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. @alvotechpr

Generics bulletin @Genericbulletin

Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey https://t.co/QrAquJiGGy

With the first approved rival to Lucentis in both the EU and US, @SamsungBioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Generics bulletin @Genericbulletin

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars https://t.co/n4BW4gBqWS

With the Big Give, @ihp_uk is raising money to get vital medicine to people who need it. For every £1 donated, IHP can send £20 worth of medicine. https://t.co/7OUni0VRNC https://t.co/iWagGz04YV

International Health Partners @ihp_uk

The @BigGive #ChristmasChallenge21 ends in 24 hours. We still have about £10,000 of match funding still available! We need your help urgently to make double the difference to the lives of people who lack access to medicine around the world: https://t.co/iRzOa3jFEy https://t.co/PU12Ci69U5

In this interview, CEO Michael Goettler provides an update on the progress made by @ViatrisInc in its first year, also previewing the detailed strategy that will be unveiled at the firm’s upcoming investor day and underlining the importance of biosimilars and complex generics.

Generics bulletin @Genericbulletin

Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars https://t.co/4wXQyfyY15

RT @ihp_uk: Thanks for a great night at the #GGBAwards. A big shout out to all the entries for this year’s #CSR Initiative of the Year awa…